Gliflumide

This classification denotes an anti-diabetic agent with the molecular formula C25H29FN4O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) USE67B01YN, chemically known as benzeneacetamide, n-((1s)-1-(5-fluoro-2-methoxyphenyl)ethyl)-4-(((5-(2-methylpropyl)-2-pyrimidinyl)amino)sulfonyl)- but more generally known as gliflumide, which bears US NIH Compound Identifier 197722. European Medicines Agency schedules Gliflumide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07924MIG. The term GLIFLUMIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 29, No. 10 1975, List 15). GLIFLUMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule gliflumide under HS 29350090 and SITC 51580. As of Q4 2014, GLIFLUMIDE remains US FDA's Preferred Term for this commodity. Gliflumide bears US NLM identifiers UMLS ID C0061322 and NCI Concept Code C72947. SMILES: S(=O)(=O)(NC1NCC(CC(C)C)CN1)C1CCC(CC(=O)NC(C2C(OC)CCC(F)C2)C)CC1.